(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 17.71% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Transmedics Group's revenue in 2026 is $635,890,000.On average, 15 Wall Street analysts forecast TMDX's revenue for 2026 to be $25,841,193,155, with the lowest TMDX revenue forecast at $24,664,048,526, and the highest TMDX revenue forecast at $26,853,827,847. On average, 15 Wall Street analysts forecast TMDX's revenue for 2027 to be $30,735,018,152, with the lowest TMDX revenue forecast at $28,928,173,725, and the highest TMDX revenue forecast at $32,903,369,708.
In 2028, TMDX is forecast to generate $35,908,786,529 in revenue, with the lowest revenue forecast at $32,315,143,003 and the highest revenue forecast at $39,537,682,184.